agilon health (AGL) Q3 2026 Earnings Call Transcript

Agilon Health reported Q3 revenue of $1.52 billion, up 6% year over year, and Adjusted EBITDA of $64 million versus a $91 million loss a year earlier, exceeding internal guidance. It raised 2026 Adjusted EBITDA guidance to $145 million–$155 million from $75 million–$95 million and revenue guidance to $5.87 billion–$5.89 billion; the Q3 medical services expense ratio improved to 88.5% from 104%. Medicare Advantage membership fell 10% year over year to 454,000 as the company exited less-profitable markets, while management cited limited Q3 paid-claims visibility and a roughly 7% cost trend.

Analysis

The earnings signal is materially lower quality than the guidance raise implies: reported improvement draws on prior-period claims development, revised risk adjustment, and favorable first-half costs, while management flags limited paid-claims visibility and uses a roughly 7% cost trend for the balance of the year. The key near-term risk is not simply medical inflation; it is a reserve reversal that can make the current run-rate look stronger just as the underlying cost trend worsens. Treat the raised outlook as a claims-development and revenue-recognition test, not yet proof of durable operating leverage.

For 1–3 months, the next claims updates and February 2027 guidance should determine whether the improvement survives without further favorable true-ups. Contracting covers a substantial portion of the book, but the expected benefit is more modest than this year's; payer economics and Stars-related upside sharing remain important variables. Over 6–18 months, expanded ACO relationships offer growth optionality, but the 12–18-month setup period and risk-bearing infrastructure mean announced membership growth is not equivalent to near-term EBITDA. Conversely, smaller MA membership may improve mix while reducing scale and revenue base; verify economics rather than treating exits as automatically accretive.

Consensus may be over-weighting the headline beat and underweighting the concentration of earnings in estimates and timing. The bull case is that clinical pathways, better data, and payer repricing make savings repeatable. That thesis is falsified by rising incurred cost trends, adverse claims development, or 2027 contracting that fails to protect unit economics. No valuation or share-price data is provided, so avoid an unconditional directional call.

Key Decisions for Investors

• Do not chase AGL on the guidance raise alone. Verify the next claims development, paid-claims completion, and medical-cost trend before underwriting the new EBITDA run-rate.
• Tactical setup: if AGL gaps materially higher on the results, consider a defined-risk put spread rather than an outright short; size against the possibility that clinical execution and contracting deliver genuinely durable improvement. Without price and option data, no entry level or spread strikes are supportable.
• Track February 2027 guidance for ACO EBITDA conversion, not just membership growth: confirm implementation timing, economics by model, and whether new growth requires incremental investment or risk-bearing capacity.
• Falsification alert for the cautious thesis: stable or improving claims trends through year-end, limited adverse prior-period development, and payer contracts that sustain economics despite a smaller contracting tail. A cost-trend or reserve deterioration would strengthen the case to fade any post-earnings rally.